We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Ascletis announces positive topline results from its U.S. SAD study of ASC30 oral tablet in obese patients, showing good PK, safety and potential for best - in - class status.